Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
Total Valuation
LENZ Therapeutics has a market cap or net worth of $783.50M. The enterprise value is $1.13B.
Market Cap$783.50M
Enterprise Value$1.13B
Share Statistics
LENZ Therapeutics has 31,289,968 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,289,968
Owned by Insiders15.46%
Owned by Institutions60.51%
Financial Efficiency
LENZ Therapeutics’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -28.53%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.53%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-8.29M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of LENZ Therapeutics is ―. LENZ Therapeutics’s PEG ratio is 0.15.
PE Ratio―
PS Ratio0.00
PB Ratio3.01
Price to Fair Value3.01
Price to FCF-10.26
Price to Operating Cash Flow-15.28
PEG Ratio0.15
Income Statement
In the last 12 months, LENZ Therapeutics had revenue of 0.00 and earned -49.77M in profits. Earnings per share was -2.34.
Revenue0.00
Gross Profit-58.00K
Operating Income-58.61M
Pretax Income-49.77M
Net Income-49.77M
EBITDA-49.71M
Earnings Per Share (EPS)-2.34
Cash Flow
In the last 12 months, operating cash flow was -45.22M and capital expenditures -938.00K, giving a free cash flow of -46.16M billion.
Operating Cash Flow-45.22M
Free Cash Flow-46.16M
Free Cash Flow per Share-1.48
Dividends & Yields
LENZ Therapeutics pays an annual dividend of $7.21, resulting in a dividend yield of ―
Dividend Per Share$7.21
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.11
52-Week Price Change-41.20%
50-Day Moving Average31.31
200-Day Moving Average31.20
Relative Strength Index (RSI)24.47
Average Volume (3m)1.08M
Important Dates
LENZ Therapeutics upcoming earnings date is Mar 25, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend DateMar 22, 2024
Financial Position
LENZ Therapeutics as a current ratio of 20.36, with Debt / Equity ratio of 0.51%
Current Ratio20.36
Quick Ratio20.36
Debt to Market Cap0.00
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, LENZ Therapeutics has paid 1.00K in taxes.
Income Tax1.00K
Effective Tax Rate>-0.01
Enterprise Valuation
LENZ Therapeutics EV to EBITDA ratio is -11.98, with an EV/FCF ratio of -9.95.
EV to Sales0.00
EV to EBITDA-11.98
EV to Free Cash Flow-9.95
EV to Operating Cash Flow-10.03
Balance Sheet
LENZ Therapeutics has $202.17M in cash and marketable securities with $461.00K in debt, giving a net cash position of $201.71M billion.
Cash & Marketable Securities$202.17M
Total Debt$461.00K
Net Cash$201.71M
Net Cash Per Share$6.45
Tangible Book Value Per Share$9.59
Margins
Gross margin is 98.44%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin98.44%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for LENZ Therapeutics is $56.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$56.60
Price Target Upside212.02% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast70.19%